Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.

已完结 10 由 weifengqingqingchui 发布于 2024/4/2 22:11:25

DOI:10.1056/NEJMoa2309169
作者：Kathleen N Moore, Antoine Angelergues, Gottfried E Konecny, Yolanda García, Susana Banerjee, Domenica Lorusso, Jung-Yun Lee, John W Moroney, Nicoletta Colombo, Andrzej Roszak, Jacqueline Tromp, Tashanna Myers, Jeong-Won Lee, Mario Beiner, Casey M Cosgrove, David Cibula, Lainie P Martin, Renaud Sabatier, Joseph Buscema, Purificación Estévez-García, Lan Coffman, Shibani Nicum, Linda R Duska, Sandro Pignata, Fernando Gálvez, Yuemei Wang, Michael Method, Anna Berkenblit, Diana Bello Roufai, Toon Van Gorp
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：Background: Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian can

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:BMJMirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer